In the first quarter, we grew year-over-year revenues significantly to $0.4 billion, driven primarily by execution of our long-term strategic partnership in -- with the U.K. government. In the U.S., ...

RNA technology is regarded as one of the newest frontiers in medicine, but in fact a primordial innovator got there way ...

Myocarditis is recognized as a rare but serious adverse reaction to messenger RNA (mRNA) vaccination against COVID-19.

A stabilized mRNA carrier turns tumor injection into broader immune activation by extending vaccine delivery to lymph nodes ...

A new study by researchers at the Icahn School of Medicine at Mount Sinai overturns a longstanding assumption about how mRNA ...

The U.S. helped pioneer the technology, but new funding cuts may shift breakthroughs — and industry leadership — overseas.

Presentations highlight AI-driven mRNA design process enabling up to 40-fold selectivity and 10-fold in vivo oncoselectivity ...

Moderna Inc. (NASDAQ:MRNA) is one of the best performing S&P 500 stocks so far in 2026. On April 21, the European Commission ...

A surprising backup system in the immune response to mRNA vaccines may hold the key to more effective cancer treatments.

The Department of Health and Human Services had canceled hundreds of millions of dollars in funding previously committed help ...

With the introduction of mRNA vaccines in the 2010s – vaccines that use messenger RNA molecules in cells to train the body to ...

For FY 2026, the company is targeting up to 10% growth over its 2025 revenue. ・Moderna’s Q1 net product sales rose on ...